- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04782102
SOPHIE: Online-intervention for Prevention and Treatment of Social Anxiety in Adolescents (SOPHIE)
August 3, 2023 updated by: University of Bern
SOPHIE: a Randomised Controlled Trial to Investigate the Efficacy of Online-intervention for Prevention and Treatment of Social Anxiety in Adolescents
This study's aim is to investigate the efficacy of the online-intervention SOPHIE.
SOPHIE is an online-intervention for adolescents with social anxiety.
In Switzerland, Germany, Austria and Liechtenstein, about one in 15 adolescents suffers from social anxiety.
The SOPHIE intervention aims to help these adolescents to better understand and cope with their social anxiety symptoms and to feel more comfortable in social situations.
The investigators intend to include 248 adolescents in the study.
Stratified by subclinical and clinical level of social anxiety, participants will be randomly assigned to the SOPHIE group or the control group receiving care-as-usual.
Both groups will complete online questionnaires and will be interviewed via telephone several times during the study.
This allows to compare the two groups regarding their efficacy of the SOPHIE programme in terms of changes in social anxiety over time.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
128
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Noemi Walder, M Sc
- Phone Number: +41316315419
- Email: noemi.walder@psy.unibe.ch
Study Contact Backup
- Name: Stefanie J Schmidt, Prof. Dr.
- Phone Number: +41 31 631 82 63
- Email: stefanie.schmidt@psy.unibe.ch
Study Locations
-
-
-
Bern, Switzerland, 3012
- University of Bern
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
11 years to 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age between 11;00 (11 years and 0 months) and 17;11 (17 years and 11 months)
- Good written and spoken German language skills
- Access to an Internet connection and a device to use the intervention (tablet, smartphone, PC) and to collect the EMA data (smartphone)
- Subclinical values on the SPIN (value: 16-23; Loscalzo et al., 2018) or criteria for social anxiety disorder according to Kinder-DIPS (Schneider et al., 2017)
- Written consent of the adolescent (if at least 14 years old) or the parents or guardian (if adolescent under 14 years old) and assent of adolescent under 14 years old
Exclusion Criteria:
- Known diagnosis of autism spectrum disorder
- Current suicidal ideation (collected via PHQ-A Item 9)
- Lack of knowledge of the German language in spoken and written form
- Past diagnosis of social anxiety according to the DSM-5 criteria assessed by the Kinder-DIPS (Schneider et al., 2017) in participants with current subclinical anxiety
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SOPHIE Intervention
SOPHIE is an online-intervention aiming to reduce social anxiety in adolescents.
SOPHIE has 8 modules, one module per week, which lasts about 60 minutes.
SOPHIE includes elements of evidence-based psychotherapeutic interventions to reduce social anxiety and of an existing online-intervention for adults with social anxiety adopted to the needs of adolescents.
The intervention consists of psychoeducation (how social anxieties arise), application examples (e.g.
setting up a personal anxiety cycle or anxiety pyramid, imagination exercise: journey to a safe place), and contains weekly tasks for which regular repetition in everyday life is important (e.g.
progressive muscle relaxation, observing anxiety in everyday life, exposures in various situations).
At the end of each module, a short quiz allows participants to recall and consolidate what they have learned.
The content is presented in video inputs, short explanatory texts, application tasks and quizzes.
|
SOPHIE is an online-intervention aiming to reduce social anxiety in adolescents.
SOPHIE has 8 modules, one module per week, which lasts about 60 minutes.
SOPHIE includes elements of evidence-based psychotherapeutic interventions to reduce social anxiety and of an existing online-intervention for adults with social anxiety adopted to the needs of adolescents.
The intervention consists of psychoeducation (how social anxieties arise), application examples (e.g.
setting up a personal anxiety cycle or anxiety pyramid, imagination exercise: journey to a safe place), and contains weekly tasks for which regular repetition in everyday life is important (e.g.
progressive muscle relaxation, observing anxiety in everyday life, exposures in various situations).
At the end of each module, a short quiz allows participants to recall and consolidate what they have learned.
The content is presented in video inputs, short explanatory texts, application tasks and quizzes.
|
No Intervention: Care-as-usual
Care-As-Usual: all other kinds of interventions are allowed and will be recorded using the Client Sociodemographic and Service Receipt Inventory (Chisholm et al., 2000; Roick et al., 2001)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in social anxiety assessed by the Social Phobia Inventory (SPIN; Connor et al., German Version: Sosic et al., 2008)
Time Frame: Baseline assessment compared to assessment at post-intervention (2 months after baseline)
|
Measure of social anxiety, total score ranging from 0 - 68 (representing the sum of each of the 17 individual items).
Lower scores represent less social anxiety and a more favourable outcome.
|
Baseline assessment compared to assessment at post-intervention (2 months after baseline)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Current and past mental disorder assessed by the structured diagnostic interview for mental disorders of childhood and adolescence (Kinder-DIPS; Schneider et al., 2017)
Time Frame: Assessed at baseline, at post-intervention (2 months after baseline) and follow-up (5 months after intervention);
|
At Baseline, the entire Kinder-DIPS will be assessed.
At post and follow-up, only the sections for social anxiety and comorbid diagnoses met at baseline are assessed.
|
Assessed at baseline, at post-intervention (2 months after baseline) and follow-up (5 months after intervention);
|
Change in global functioning assessed by the GF Social (Cornblatt et al., 2007)
Time Frame: Assessed at baseline, at post-intervention (2 months after baseline) and follow-up (5 months after intervention)
|
Structured interview assessing the level of functioning in social areas of life (friends & family) ranging from 1 to 10, higher scores indicate a better level of functioning
|
Assessed at baseline, at post-intervention (2 months after baseline) and follow-up (5 months after intervention)
|
Change in global functioning assessed by the GF Role Scale (Cornblatt et al., 2007)
Time Frame: Assessed at baseline, at post-intervention (2 months after baseline) and follow-up (5 months after intervention)
|
Structured interview assessing the level of functioning in school / work ranging from 1 to 10, higher scores indicate a better level of functioning
|
Assessed at baseline, at post-intervention (2 months after baseline) and follow-up (5 months after intervention)
|
Utilisation of help assessed by the Client Sociodemographic and Service Receipt Inventory (CSSRI-EU; Chisholm et al., 2000; Roick et al., 2001)
Time Frame: Assessed at post-intervention (2 months after baseline) and follow-up (5 months after baseline)
|
Structured interview assessing the additional use of psychological, medical and other formal and informal services and sources of help (e.g. at school, friends)
|
Assessed at post-intervention (2 months after baseline) and follow-up (5 months after baseline)
|
Change of fear of negative evaluation and avoidance assessed by the Social Anxiety Scale for Adolescents (SAS-A; La Greca & Lopez,1998)
Time Frame: Assessed at baseline, at mid-treatment (1 month after baseline), at post-intervention (2 months after baseline), and at follow-up (5 months after baseline)
|
Total score ranging from 18 - 90 (representing the sum of each of the 18 individual items).
Lower scores represent less fear of negative evaluation and avoidance and a more favourable outcome.
|
Assessed at baseline, at mid-treatment (1 month after baseline), at post-intervention (2 months after baseline), and at follow-up (5 months after baseline)
|
Change of generalized anxiety symptoms assessed by the Generalized Anxiety Disorder 7 (GAD-7; Löwe et al., 2008) questionnaire
Time Frame: Assessed at baseline, at mid-treatment (1 month after baseline), at post-intervention (2 months after baseline), and at follow-up (5 months after baseline)
|
Total score ranging from 7 - 35 (representing the sum of each of the 7 individual items).
Lower scores represent less anxiety and a more favourable outcome.
|
Assessed at baseline, at mid-treatment (1 month after baseline), at post-intervention (2 months after baseline), and at follow-up (5 months after baseline)
|
Change in depressive symptoms assessed by the Patient Health Questionnaire-9 for Adolescents (PHQ-A; Johnson et al., 2002)
Time Frame: Assessed at baseline, at mid-treatment (1 month after baseline), at post-intervention (2 months after baseline), and at follow-up (5 months after baseline)
|
Total score ranging from 0 - 27 (representing the sum of each of the 9 individual items).
Lower scores represent less depressive symptoms and a more favourable outcome.
|
Assessed at baseline, at mid-treatment (1 month after baseline), at post-intervention (2 months after baseline), and at follow-up (5 months after baseline)
|
Change in health-related quality of life assessed by the KIDSCREEN-10 (Ravens-Sieberer et al., 2010)
Time Frame: Assessed at baseline, at mid-treatment (1 month after baseline), at post-intervention (2 months after baseline), and at follow-up (5 months after baseline)
|
Total score ranging from 11 - 55 (representing the sum of each of the 11 individual items).
Higher scores represent a higher quality of life and a more favourable outcome.
|
Assessed at baseline, at mid-treatment (1 month after baseline), at post-intervention (2 months after baseline), and at follow-up (5 months after baseline)
|
Change in self-esteem assessed by the Rosenberg Self-Esteem Scale (RSES; Rosenberg, 1965)
Time Frame: Assessed at baseline, at mid-treatment (1 month after baseline), at post-intervention (2 months after baseline), and at follow-up (5 months after baseline)
|
Total score ranging from 0 - 30 (representing the sum of each of the 10 individual items).
Higher scores represent a higher self-esteem and a more favourable outcome.
|
Assessed at baseline, at mid-treatment (1 month after baseline), at post-intervention (2 months after baseline), and at follow-up (5 months after baseline)
|
Change in social anxiety assessed by the Social Phobia Inventory (SPIN; Connor et al., German Version: Sosic et al., 2008)
Time Frame: Assessed at baseline, at mid-treatment (1 month after baseline), at post-intervention (2 months after baseline), and at follow-up (5 months after baseline)
|
Measure of social anxiety, total score ranging from 0 - 68 (representing the sum of each of the 17 individual items).
Lower scores represent less social anxiety and a more favourable outcome.
|
Assessed at baseline, at mid-treatment (1 month after baseline), at post-intervention (2 months after baseline), and at follow-up (5 months after baseline)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence to the Online-Intervention
Time Frame: During the eight-week online-intervention
|
Assessed within the online-intervention.
Indicator of adherence: time spent in program.
|
During the eight-week online-intervention
|
Adherence to the Online-Intervention
Time Frame: During the eight-week online-intervention
|
Assessed within the online-intervention.
Indicator of adherence: number of clicks.
|
During the eight-week online-intervention
|
Adherence to the Online-Intervention
Time Frame: During the eight-week online-intervention
|
Assessed within the online-intervention.
Indicator of adherence: number of modules completed.
|
During the eight-week online-intervention
|
Adherence to the Online-Intervention
Time Frame: During the eight-week online-intervention
|
Assessed within the online-intervention.
Indicator of adherence: number of exercises completed.
|
During the eight-week online-intervention
|
Negative effects of the online-intervention
Time Frame: Assessed at post-intervention (2 months after baseline)
|
Assessed with the Inventar zur Erfassung Negativer Effekte in der Psychotherapie für Kinder (Kinder-INEP; Bieda et al., 2018).
Total score ranging from -3 - 38 (representing the sum of each of the 15 individual items).
Higher scores represent more negative effects of the online-intervention and a less favourable outcome.
|
Assessed at post-intervention (2 months after baseline)
|
Satisfaction with the online-intervention assessed by the Zufriedenheit mit der Intervention (ZUF-8; Schmidt et al., 1989) questionnaire
Time Frame: Assessed at post-intervention (2 months after baseline)
|
Total score ranging from 8 - 32 (representing the sum of each of the 8 individual items).
Higher scores represent more satisfaction and a more favourable outcome.
|
Assessed at post-intervention (2 months after baseline)
|
Therapeutic alliance assessed by the Working Alliance Inventory for Guided Internet Interventions (WAI-I; Gómez Penedo et al., 2020)
Time Frame: Assessed 2, 4, 6, and 8 weeks after baseline (during the online-intervention every two weeks)
|
Total score ranging from 12 - 60 (representing the sum of each of the 12 individual items).
Higher scores represent a higher working alliance and a more favourable outcome.
|
Assessed 2, 4, 6, and 8 weeks after baseline (during the online-intervention every two weeks)
|
Motivation of adolescent for the online-intervention assessed with the Motivation for Youth's Treatment Scale (MYTS; Breda & Riemer, 2012) youth version
Time Frame: Assessed at baseline and every two week during the eight week online-intervention (after 2, 4, 6, and 8 weeks)
|
Total score ranging from 8 - 40 (representing the sum of each of the 8 individual items).
Higher scores represent more motivation and a more favourable outcome.
|
Assessed at baseline and every two week during the eight week online-intervention (after 2, 4, 6, and 8 weeks)
|
Motivation of parent / guardian for the online-intervention assessed with the Motivation for Youth's Treatment Scale (MYTS; Breda & Riemer, 2012) parent version
Time Frame: Baseline, mid-intervention(after 1 Month), and at post-intervention (after 2 months)
|
Total score ranging from 8 - 40 (representing the sum of each of the 8 individual items).
Higher scores represent more motivation and a more favourable outcome.
|
Baseline, mid-intervention(after 1 Month), and at post-intervention (after 2 months)
|
Adolescents' expectation of the online-intervention assessed with the Credibility/Expectancies Questionnaire (CEQ; Devilly & Borkovec, 2000) youth version
Time Frame: Assessed at baseline
|
Total score ranging from 4 - 36 (representing the sum of each of the 4 individual items) and two items indicating percents from 0-100.
Higher scores represent higher expectations of the online-intervention.
|
Assessed at baseline
|
Parents' / Guardians' expectation of the online-intervention assessed with the Credibility/Expectancies Questionnaire (CEQ; Devilly & Borkovec, 2000) parent version
Time Frame: Assessed at baseline
|
Total score ranging from 4 - 36 (representing the sum of each of the 4 individual items) and two items indicating percents from 0-100.
Higher scores represent higher expectations of the online-intervention.
|
Assessed at baseline
|
Ecological Momentary Assessment (EMA)
Time Frame: 3 times a day during the eight week online-intervention, and three times a day for the two succeeding weeks after the follow-up assessment (5 months after baseline).
|
The Ecological Momentary Assessment consists of 20 short questions asking about the momentary social context, the momentary affect (Positive and negative affective schedule for children; PANAS-C; Ebesutani et al., 2012) and factors maintaining social anxiety (derived from the Social phobia weekly summary scale; SPWSS; Clark et al., 2003).
|
3 times a day during the eight week online-intervention, and three times a day for the two succeeding weeks after the follow-up assessment (5 months after baseline).
|
Change in parents' / guardians' assessment of their children's social anxieties assessed by the Elternfragebogen zu sozialen Ängsten im Kindes- und Jugendalter (ESAK, van Gemmeren et al., 2008)
Time Frame: Assessed at baseline, at mid-treatment (1 month after baseline), at post-intervention (2 months after baseline), and at follow-up (5 months after baseline)
|
Total score ranging from 18 - 72 (representing the sum of each of the 18 individual items).
Lower scores represent less social anxiety and a more favorable outcome.
|
Assessed at baseline, at mid-treatment (1 month after baseline), at post-intervention (2 months after baseline), and at follow-up (5 months after baseline)
|
Interview with adolescents in the intervention group on satisfaction with the online intervention
Time Frame: Assessed at post-intervention (2 months after randomization)
|
Qualitative Interview
|
Assessed at post-intervention (2 months after randomization)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Stefanie J Schmidt, Prof. Dr., University of Bern
- Study Chair: Thomas Berger, Prof. Dr., University of Bern
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 7, 2021
Primary Completion (Estimated)
December 31, 2023
Study Completion (Estimated)
December 31, 2023
Study Registration Dates
First Submitted
March 1, 2021
First Submitted That Met QC Criteria
March 1, 2021
First Posted (Actual)
March 4, 2021
Study Record Updates
Last Update Posted (Actual)
August 4, 2023
Last Update Submitted That Met QC Criteria
August 3, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-02501
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Social Anxiety
-
Aya Technologies LimitedCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)United Kingdom
-
Tel Aviv UniversityCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)Israel
-
University of ManchesterManchester University NHS Foundation TrustCompletedSocial Anxiety | Social Anxiety Disorder | Social PhobiaUnited Kingdom
-
Aya Technologies LimitedCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)United Kingdom
-
University of BernUniversity of LuebeckActive, not recruitingSocial Anxiety Disorder (Social Phobia)Switzerland
-
University of Wisconsin, MilwaukeeTerminatedSocial Anxiety | Social Anxiety DisorderUnited States
-
Weill Medical College of Cornell UniversityBrain & Behavior Research FoundationTerminatedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder of ChildhoodUnited States
-
Stockholm UniversityPBM; MimerseCompletedSocial Anxiety | Public Speaking | Social Anxiety Disorder, Performance OnlySweden
-
Tufts UniversityCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder of ChildhoodUnited States
-
University of California, San DiegoRecruiting
Clinical Trials on SOPHIE Intervention
-
Boston Medical CenterWithdrawnAnxiety | Advanced Cancer | Depression Chronic
-
Planmed OyWithdrawnBreast CancerUnited States
-
Biolux Research Holdings, Inc.TerminatedOrthodontic Tooth MovementCanada
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedColorectal Carcinoma | Healthy Subject | Health Status UnknownUnited States
-
University of FloridaCompletedSensitivityUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Institute on Minority Health and...RecruitingHuman Papillomavirus InfectionUnited States
-
Ohio State University Comprehensive Cancer CenterCompleted
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnCancer Survivor | Peripheral Sensory Neuropathy
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditionsUnited States
-
Nottingham Trent UniversityUnknownOverweight and ObesityUnited Kingdom